ClinicalTrials.Veeva

Menu

Epidemiology and Outcome of Anaphylactic Shocks Admitted to Intensive Care Unit (ANAPHYLASHOCK)

C

Central Hospital, Nancy, France

Status

Completed

Conditions

Anaphylaxis

Study type

Observational

Funder types

Other

Identifiers

NCT04290507
ANAPHYLASHOCK/Guerci

Details and patient eligibility

About

Anaphylaxis is a severe life-threatening reaction following exposure to an antigen. Its incidence is progressively increasing in the general population over years, accompanied with an increased number of hospitalizations. Although rare, this condition is often associated with a significant morbidity and mortality. The mortality rate has been recently estimated at 0.84 (95% CI, 0.79 to 0.88) per million per year in the French adult population. Age, chronic medication and cardiac or pulmonary comorbidities have been reported to increase the risk of a severe reaction. Obesity, age and cardiovascular comorbidities have been identified as risk factors for fatal anaphylaxis. However, the risk factors for death after ICU admission have not been elucidated yet.

Enrollment

339 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Being > 18 years old
  • suffered an anaphylactic reaction, regardless of the location or causative allergen
  • transferred alive in an ICU

Exclusion criteria

  • dead within less than one hour after admission

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems